We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Asks for Additional Data To Approve Arena’s Lorcaserin
FDA Asks for Additional Data To Approve Arena’s Lorcaserin
October 29, 2010
Drugmakers developing prescription weight-loss drugs have a high hurdle to gain agency approval if the FDA’s action letter to Arena Pharmaceuticals regarding its lorcaserin NDA is any indication.